Table 5. Correlation of FIGO staging and histological diagnosis with survival.
Alive n/% | Dead n/% | P-value | |
Staging | |||
1A (2) | 1 (50.0) | 1 (50.0) | |
1B (13) | 10 (76.9) | 3 (23.1) | |
IIA (19) | 16 (84.2) | 3 (15.8) | |
IIB (69) | 59 (85.5) | 10 (14.5) | 0.001 |
IIIA (35) | 21(60.0) | 14 (40.0) | |
IIIB (50) | 33 (66.0) | 17 (34.0) | |
IV A (13) | 4 (30.8) | 9 (69.2) | |
IV B (8) | 1 (12.5) | 7 (87.5) | |
Total. | 145 (69.4) | 64 (30.6) | |
HPE (SCC) results | |||
Well Differentiated | 37 (27.6) | 7 (12.3) | |
Moderately | 56 (41.8) | 30 (52.6) | |
Poorly | 36 (26.9) | 19 (33.3) | 0.046 |
Keratinizing | 2 (1.5) | 1 (1.8) | |
Large non-Keratinizing | 3 (2.2) | 0 (0.0) | |
Total. | 134 (70.2) | 57 (29.8) |
Patients with poorly differentiated SCC were more than 2.5 times likely to die as compared to those with well differentiated SCC, while those with more advanced disease staging had as expected, higher death rates (p<0.46, and 0.001 respectively). Even after adjusting for age and HIV status using multivariate cox proportional hazards regression analysis and multinomial logistic regression, the disease stage was significantly associated with overall survival.